Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia
Tóm tắt
Từ khóa
Tài liệu tham khảo
Heller H, Kariv J, Sherf L, Sohar E (1955) Familial Mediterranean fever. Harefuah 48(5):91–94
Soylemezoglu O, Kandur Y, Gonen S, Duzova A, Ozcakar ZB, Fidan K, Yalcinkaya F (2016) Familial Mediterranean fever gene mutation frequencies in a sample Turkish population. Clin Exp Rheumatol 34(6 Suppl 102):97–100
Alghamdi M (2017) Familial Mediterranean fever, review of the literature. Clin Rheumatol 36(8):1707–1713. https://doi.org/10.1007/s10067-017-3715-5
Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, Gumucio DL, Shoham NG, Kastner DL (2008) The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood 112(5):1794–1803. https://doi.org/10.1182/blood-2008-01-134932
Doerr W (1985) Cohnheim's inflammation doctrine and the current debate. Zentralblatt fur allgemeine Pathologie u pathologische Anatomie 130(4):299–306
Nakamura S, Matsumoto T (2013) Helicobacter pylori and gastric mucosa-associated lymphoid tissue lymphoma: recent progress in pathogenesis and management. World J Gastroenterol 19(45):8181–8187. https://doi.org/10.3748/wjg.v19.i45.8181
Koizumi T, Kamata T, Nakamura M, Sugawa Y, Mitsuya N (1970) Case of primary cancer of the liver developing in the course of chronic hepatitis. Nihon rinsho Jpn J Clin Med 28(2):316–319
Johnson TM, Orr TG (1948) Carcinoma of the colon secondary to chronic ulcerative colitis. Am J Dig Dis 15(1):21–23
Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Investig 125(9):3347–3355. https://doi.org/10.1172/jci80007
Moynihan KD, Irvine DJ (2017) Roles for innate immunity in combination immunotherapies. Cancer Res 77(19):5215–5221. https://doi.org/10.1158/0008-5472.Can-17-1340
Kantono M, Guo B (2017) Inflammasomes and cancer: the dynamic role of the inflammasome in tumor development. Front Immunol 8:1132. https://doi.org/10.3389/fimmu.2017.01132
Ozen S, Batu ED, Demir S (2017) Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management. Front Immunol 8:253. https://doi.org/10.3389/fimmu.2017.00253
Na SJ, Kang MJ, Yu DS, Han KD, Lee JH, Park YG, Lee YB (2018) Cancer risk in patients with Behcet disease: a nationwide population-based dynamic cohort study from Korea. J Am Acad Dermatol 78(3):464–470.e462. https://doi.org/10.1016/j.jaad.2017.09.035
Yu KH, Kuo CF, Huang LH, Huang WK, See LC (2016) Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a nationwide population-based dynamic cohort study in Taiwan. Medicine (Baltimore) 95(18):e3540. https://doi.org/10.1097/md.0000000000003540
Wang LH, Wang WM, Hsu SM, Lin SH, Shieh CC (2015) Risk of overall and site-specific cancers in Behcet disease: a nationwide population-based study in Taiwan. J Rheumatol 42(5):879–884. https://doi.org/10.3899/jrheum.140770
Brenner R, Ben-Zvi I, Shinar Y, Liphshitz I, Silverman B, Peled N, Levy C, Ben-Chetrit E, Livneh A, Kivity S (2018) Familial Mediterranean fever and incidence of cancer: an analysis of 8,534 Israeli patients with 258,803 person-years. Arthritis Rheumatol 70(1):127–133. https://doi.org/10.1002/art.40344
Turkish National Cancer Registry (TNCR) (2014). https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri/yillar/495-2014-yılı-türkiye-kanser-istatistikleri.html. Accessed 1 July 2018
Berger NA (2014) Obesity and cancer pathogenesis. Ann N Y Acad Sci 1311:57–76. https://doi.org/10.1111/nyas.12416
Ben-Zvi I, Livneh A (2011) Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 7(2):105–112. https://doi.org/10.1038/nrrheum.2010.181
Brito-Zeron P, Kostov B, Fraile G, Caravia-Duran D, Maure B, Rascon FJ, Zamora M, Casanovas A, Lopez-Dupla M, Ripoll M, Pinilla B, Fonseca E, Akasbi M, de la Red G, Duarte-Millan MA, Fanlo P, Guisado-Vasco P, Perez-Alvarez R, Chamorro AJ, Morcillo C, Jimenez-Heredia I, Sanchez-Berna I, Lopez-Guillermo A, Ramos-Casals M (2017) Characterization and risk estimate of cancer in patients with primary Sjogren syndrome. J Hematol Oncol 10(1):90. https://doi.org/10.1186/s13045-017-0464-5
Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcon GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Senecal JL, Zummer M, Pope JE, Ensworth S, El-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St Pierre Y, Clarke AE (2013) Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 42:130–135. https://doi.org/10.1016/j.jaut.2012.12.009
Silman AJ, Petrie J, Hazleman B, Evans SJ (1988) Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 47(12):988–992
Larocque K, Ovadje P, Djurdjevic S, Mehdi M, Green J, Pandey S (2014) Novel analogue of colchicine induces selective pro-death autophagy and necrosis in human cancer cells. PLoS One 9(1):e87064. https://doi.org/10.1371/journal.pone.0087064
Yunos NM, Beale P, Yu JQ, Strain D, Huq F (2010) Studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines. Anticancer Res 30(10):4025–4037
Lin ZY, Wu CC, Chuang YH, Chuang WL (2013) Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci 93(8):323–328. https://doi.org/10.1016/j.lfs.2013.07.002
La Regina G, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Sisinni L, Bolognesi A, Rensen WM, Miele A, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Brancale A, Novellino E, Dondio G, Vultaggio S, Varasi M, Mercurio C, Hamel E, Lavia P, Silvestri R (2014) New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer. J Med Chem 57(15):6531–6552. https://doi.org/10.1021/jm500561a
Lin ZY, Kuo CH, Wu DC, Chuang WL (2016) Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Kaohsiung J Med Sci 32(2):68–73. https://doi.org/10.1016/j.kjms.2015.12.006
Kuo MC, Chang SJ, Hsieh MC (2015) Colchicine significantly reduces incident cancer in gout male patients: a 12-year cohort study. Medicine (Baltimore) 94(50):e1570. https://doi.org/10.1097/md.0000000000001570
Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ (2017) Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet (London, England) 390(10105):1833–1842. https://doi.org/10.1016/s0140-6736(17)32247-x
Giat E, Ehrenfeld M, Shoenfeld Y (2017) Cancer and autoimmune diseases. Autoimmun Rev 16(10):1049–1057. https://doi.org/10.1016/j.autrev.2017.07.022
Raaschou P, Soderling J, Turesson C, Askling J, Group AS (2018) Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study. Ann Intern Med 169(5):291–299. https://doi.org/10.7326/M17-2812
van der Hilst JC, Simon A, Drenth JP (2005) Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 5(3):87–98. https://doi.org/10.1007/s10238-005-0071-6
Hemminki K, Li X, Forsti A, Sundquist J, Sundquist K (2014) Cancer risk in amyloidosis patients in Sweden with novel findings on non-Hodgkin lymphoma and skin cancer. Ann Oncol 25(2):511–518. https://doi.org/10.1093/annonc/mdt544
Barrott JJ, Kafchinski LA, Jin H, Potter JW, Kannan SD, Kennedy R, Mosbruger T, Wang WL, Tsai JW, Araujo DM, Liu T, Capecchi MR, Lazar AJ, Jones KB (2016) Modeling synovial sarcoma metastasis in the mouse: PI3’-lipid signaling and inflammation. J Exp Med 213(13):2989–3005. https://doi.org/10.1084/jem.20160817
Maturu P (2016) The inflammatory microenvironment in wilms tumors. In: van den Heuvel-Eibrink MM (ed) Wilms tumor. Codon Publications, Brisban. https://doi.org/10.15586/codon.wt.2016.ch12 (Copyright: The Author)
Sowers JL, Johnson KM, Conrad C, Patterson JT, Sowers LC (2014) The role of inflammation in brain cancer. Adv Exp Med Biol 816:75–105. https://doi.org/10.1007/978-3-0348-0837-8_4
Thieblemont C, Bertoni F, Copie-Bergman C, Ferreri AJ, Ponzoni M (2014) Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. Semin Cancer Biol 24:33–42. https://doi.org/10.1016/j.semcancer.2013.11.005
Ting JP, Duncan JA, Lei Y (2010) How the noninflammasome NLRs function in the innate immune system. Science 327(5963):286–290. https://doi.org/10.1126/science.1184004
Lukens JR, Kanneganti TD (2014) Beyond canonical inflammasomes: emerging pathways in IL-1-mediated autoinflammatory disease. Semin Immunopathol 36(5):595–609. https://doi.org/10.1007/s00281-014-0434-8
Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, Quadroni M, Drexler SK, Tschopp J (2012) Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 36(3):388–400. https://doi.org/10.1016/j.immuni.2012.01.018
Shouval DS, Biswas A, Kang YH, Griffith AE, Konnikova L, Mascanfroni ID, Redhu NS, Frei SM, Field M, Doty AL, Goldsmith JD, Bhan AK, Loizides A, Weiss B, Yerushalmi B, Yanagi T, Lui X, Quintana FJ, Muise AM, Klein C, Horwitz BH, Glover SC, Bousvaros A, Snapper SB (2016) Interleukin 1beta mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency. Gastroenterology 151(6):1100–1104. https://doi.org/10.1053/j.gastro.2016.08.055
Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD (2010) IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J İmmunol (Baltimore, Md: 1950) 185(8):4912–4920. https://doi.org/10.4049/jimmunol.1002046
Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J, Yazdi AS (2012) Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci USA 109(45):18384–18389. https://doi.org/10.1073/pnas.1209171109
Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, Dinarello CA, Fujita M (2010) Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 285(9):6477–6488. https://doi.org/10.1074/jbc.M109.064907
Guo B, Fu S, Zhang J, Liu B, Li Z (2016) Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci Rep 6:36107. https://doi.org/10.1038/srep36107
Daley D, Mani VR, Mohan N, Akkad N, Pandian G, Savadkar S, Lee KB, Torres-Hernandez A, Aykut B, Diskin B, Wang W, Farooq MS, Mahmud AI, Werba G, Morales EJ, Lall S, Wadowski BJ, Rubin AG, Berman ME, Narayanan R, Hundeyin M, Miller G (2017) NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J Exp Med 214(6):1711–1724. https://doi.org/10.1084/jem.20161707